Who owns MARINUS PHARMACEUTICALS INC?
- Ticker: MRNS
- CUSIP Number: 56854q200
Tip: Access positions for across all investors
Analyze quarterly positions in Marinus Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Marinus Pharmaceuticals stock
Who bought or sold MARINUS PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Suvretta Capital Management | 5.1M | $46M | -2% | Mar 2024 |
|
| BlackRock | 4.7M | $43M | 14% | Mar 2024 |
|
| Franklin Resources | 3.5M | $32M | -9% | Mar 2024 |
|
| Sofinnova Ventures | 3.3M | $29M | 149% | Mar 2024 |
|
| Cormorant Asset Management | 3.3M | $29M | 0% | Mar 2024 |
|
| venBio Select Advisor | 3.2M | $34M | 0% | Dec 2023 |
|
| Jennison Associates | 3.0M | $27M | 0% | Mar 2024 |
|
| Vanguard Group | 2.8M | $25M | 5% | Mar 2024 |
|
| Eventide Asset Management | 2.3M | $21M | -48% | Mar 2024 |
|
| Adage Capital Partners GP | 2.3M | $21M | -20% | Mar 2024 |
|
| Lion Point Capital | 2.1M | $19M | -1% | Mar 2024 |
|
| Bleichroeder | 1.9M | $20M | 0% | Dec 2023 |
|
| GMT Capital Corp | 1.6M | $15M | -5% | Mar 2024 |
|
| Citadel Advisors | 1.5M | $13M | 104% | Mar 2024 |
|
| Bain Capital Life Sciences Investors | 1.4M | $13M | -3% | Mar 2024 |
|
| Geode Capital Management | 1.2M | $11M | 16% | Mar 2024 |
|
| Woodline Partners | 1.2M | $11M | 88% | Mar 2024 |
|
| Ikarian Capital | 1.1M | $9.5M | 41% | Mar 2024 |
|
| Balyasny Asset Management | 849k | $7.7M | 100% | Mar 2024 |
|
| Susquehanna International | 608k | $5.5M | 88% | Mar 2024 |
|
| Superstring Capital Management | 566k | $5.1M | 22% | Mar 2024 |
|
| Standard Life Aberdeen | 553k | $5.0M | 0% | Mar 2024 |
|
| Point72 Asset Management | 492k | $4.4M | 0% | Mar 2024 |
|
| Northern Trust | 470k | $4.2M | 9% | Mar 2024 |
|
| Caption Management | 453k | $4.1M | 41% | Mar 2024 |
|
| Morgan Stanley | 408k | $3.7M | 766% | Mar 2024 |
|
| Boothbay Fund Management | 278k | $2.5M | -65% | Mar 2024 |
|
| Assenagon Asset Management | 271k | $2.5M | 0% | Mar 2024 |
|
| Wellington Management Company | 241k | $2.6M | 55% | Dec 2023 |
|
| Walleye Trading Advisors | 185k | $1.7M | -30% | Mar 2024 |
|
| Propel Bio Management | 180k | $1.6M | 0% | Mar 2024 |
|
| Altium Capital Management | 177k | $1.6M | 41% | Mar 2024 |
|
| Jane Street | 168k | $1.5M | 71% | Mar 2024 |
|
| Qube Research & Technologies | 167k | $1.5M | 100% | Mar 2024 |
|
| Exome Asset Management | 163k | $1.5M | 100% | Mar 2024 |
|
| Bank of New York Mellon | 160k | $1.4M | -6% | Mar 2024 |
|
| Charles Schwab Investment Management | 155k | $1.4M | 4% | Mar 2024 |
|
| Simplify Asset Management | 150k | $1.4M | 0% | Mar 2024 |
|
| Nuveen Asset Management | 140k | $1.3M | 1% | Mar 2024 |
|
| Goldman Sachs Group | 136k | $1.2M | 88% | Mar 2024 |
|
| UBS Group | 124k | $1.1M | 49% | Mar 2024 |
|
| LMR Partners | 120k | $1.1M | 100% | Mar 2024 |
|
| HAP Trading | 101k | $16k | -60% | Mar 2024 |
|
| Simplex Trading | 92k | $834k | 100% | Mar 2024 |
|
| Bank of America Corporation | 91k | $820k | 98% | Mar 2024 |
|
| Rhumbline Advisers | 77k | $697k | 2% | Mar 2024 |
|
| Barclays | 76k | $685k | -1% | Mar 2024 |
|
| Hussman Econometrics Advisors | 74k | $664k | 100% | Mar 2024 |
|
| Campbell & Co. Investment Adviser | 70k | $628k | 100% | Mar 2024 |
|
| J. Goldman & Co | 68k | $610k | 100% | Mar 2024 |
|
| Sherbrooke Park Advisers | 65k | $585k | 100% | Mar 2024 |
|
| Victory Capital Management | 61k | $553k | -26% | Mar 2024 |
|
| Wolverine Trading | 54k | $487k | 128% | Mar 2024 |
|
| Leucadia National Corporation | 53k | $481k | -75% | Mar 2024 |
|
| Trexquant Investment | 51k | $553k | 100% | Dec 2023 |
|
| Two Sigma Investments | 43k | $387k | 4% | Mar 2024 |
|
| Two Sigma Advisers | 43k | $386k | 100% | Mar 2024 |
|
| Jacobs Levy Equity Management | 42k | $384k | 100% | Mar 2024 |
|
| Belvedere Trading | 42k | $384k | -46% | Mar 2024 |
|
| Alliancebernstein | 39k | $427k | 13% | Dec 2023 |
|
| Springbok Capital Management | 38k | $340k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 34k | $304k | -24% | Mar 2024 |
|
| Grimes & Company | 34k | $303k | -2% | Mar 2024 |
|
| Millennium Management | 32k | $290k | 25% | Mar 2024 |
|
| T. Rowe Price Associates | 31k | $280k | 9% | Mar 2024 |
|
| MetLife Investment Advisors | 26k | $287k | 0% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 26k | $234k | 3% | Mar 2024 |
|
| Y-Intercept | 26k | $233k | 100% | Mar 2024 |
|
| American International | 25k | $274k | 0% | Dec 2023 |
|
| Graham Capital Management | 21k | $186k | 100% | Mar 2024 |
|
| AQR Capital Management | 18k | $166k | -20% | Mar 2024 |
|
| New York State Common Retirement Fund | 17k | $155k | 0% | Mar 2024 |
|
| Ing Investment Management | 17k | $154k | -17% | Mar 2024 |
|
| Gts Securities | 17k | $154k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 16k | $148k | 17% | Mar 2024 |
|
| Citigroup | 14k | $125k | 67% | Mar 2024 |
|
| ProShare Advisors | 14k | $124k | 100% | Mar 2024 |
|
| Denali Advisors | 14k | $123k | 0% | Mar 2024 |
|
| Ameriprise Financial | 13k | $116k | 100% | Mar 2024 |
|
| Parallax Volatility Advisers | 13k | $115k | 100% | Mar 2024 |
|
| Fox Run Management | 11k | $96k | 100% | Mar 2024 |
|
| China Universal Asset Management | 11k | $95k | 66% | Mar 2024 |
|
| Values First Advisors | 10k | $94k | -27% | Mar 2024 |
|
| Advisor Group Holdings | 6.1k | $55k | 4% | Mar 2024 |
|
| Legal & General Group | 5.5k | $50k | -1% | Mar 2024 |
|
| California State Teachers Retirement System | 5.5k | $50k | -51% | Mar 2024 |
|
| Summit Investment Advisors | 5.2k | $48k | 0% | Mar 2024 |
|
| Coppell Advisory Solutions | 5.0k | $54k | 100% | Dec 2023 |
|
| FMR | 2.9k | $26k | -36% | Mar 2024 |
|
| Group One Trading | 2.8k | $25k | -46% | Mar 2024 |
|
| Metropolitan Life Insurance Company | 2.7k | $30k | 0% | Dec 2023 |
|
| Royal Bank of Canada | 2.3k | $22k | -85% | Mar 2024 |
|
| Zurcher Kantonalbank | 1.8k | $16k | -32% | Mar 2024 |
|
| Amalgamated Bank | 1.7k | $15k | -76% | Mar 2024 |
|
| Tower Research Capital | 358.00 | $3.2k | -95% | Mar 2024 |
|
| Absolute Investment Management | 351.00 | $3.2k | -66% | Mar 2024 |
|
| Hanson McClain Advisors | 317.00 | $2.9k | 20% | Mar 2024 |
|
| Signature | 277.00 | $2.5k | -19% | Mar 2024 |
|
| Lindbrook Capital | 242.00 | $2.2k | 0% | Mar 2024 |
|
| Daiwa Securities Group | 202.00 | $2.0k | 248% | Mar 2024 |
|
| Torno Capital | 200.00 | $1.8k | -99% | Mar 2024 |
|
| Fifth Third Bancorp | 115.00 | $1.0k | 0% | Mar 2024 |
|
| Brian McDonald | 93.00 | $840.999000 | 100% | Mar 2024 |
|
| Pnc Financial Services | 84.00 | $758.998800 | 1100% | Mar 2024 |
|
| NISA Investment Advisors | 76.00 | $687.002000 | 533% | Mar 2024 |
|
| GAMMA Investing | 56.00 | $505.999200 | 40% | Mar 2024 |
|
| Harbor Investment Advisory | 37.00 | $333.999000 | 0% | Mar 2024 |
|
| Quadrant Capital | 22.00 | $199.001000 | 0% | Mar 2024 |
|
| Farther Finance Advisors | 14.00 | $126.000000 | 0% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 11.00 | $99.000000 | 100% | Mar 2024 |
|
Who sold out of Marinus Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Opaleye Management | Dec 2023 | 564k | $6.1M |
| Alpha DNA Investment Management | Dec 2023 | 50k | $540k |
| Mach-1 Financial Group | Dec 2023 | 44k | $476k |
| AE Wealth Management | Dec 2023 | 43k | $434k |
| Dimensional Fund Advisors | Dec 2023 | 29k | $317k |
| Mirae Asset Global Investments | Dec 2023 | 25k | $277k |
| Walleye Trading | Dec 2023 | 15k | $166k |
| Florida State Board of Administration | Dec 2023 | 15k | $157k |
| SG Americas Securities | Dec 2023 | 12k | $134k |
| Corton Capital | Dec 2023 | 11k | $120k |
| Advisory Services Network | Dec 2023 | 76.00 | $825.998400 |
| Federated Investors | Sep 2023 | 50.00 | $403.000000 |
| SOA Wealth Advisors | Dec 2023 | 40.00 | $435.000000 |